Using machine learning to distill 50K oncology abstracts to 355 principal topics and tracking how these topics have evolved over the last decade
Author: Arseniy Shabashvili
Disclaimer: I am not a licensed investment or medical professional, and the ideas herein are in no way intended as investment or medical advice. I do not have any personal […]
Go back to the inaugural post Go back to Part 1 of the post Survival Analysis Model of R&D Risk This is the second part of the two-part series on […]
Go back to the inaugural post Jump to Part 2 of the post Biotech Risk Models Biotech equities are derivative securities. Their value is derived from intellectual property rights (patents). […]
This is the inaugural post of my blog on biotech finance. With this post, I aim to accomplish three things: Identify the main challenge of the life sciences industry: the […]